VJOncology is committed to improving our service to you

ASCO 2020 | Updates from COMBI-AD: dabrafenib and trametinib for melanoma

VJOncology is committed to improving our service to you

Axel Hauschild

Axel Hauschild, MD, of the University of Schleswig-Holstein, Kiel, Germany, outlines five-year analysis of COMBI-AD (NCT01682083), a study evaluating the long-term benefit of adjuvant dabrafenib and trametinib in patients with resected stage III BRAF V600–mutant melanoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter